Products

d-Nav System
Hygieia
Endocrinology & Metabolic AI
Hygieia's d-Nav System is an FDA-cleared, AI-driven mobile app and virtual clinical support program for autonomous insulin dose adjustments in adults with Type 2 diabetes.

See all 1 product →

About Hygieia

Hygieia is a pioneering digital therapeutics company focused on revolutionizing insulin management for individuals with type 2 diabetes. Its flagship offering, the d-Nav® Insulin Management Program, leverages advanced AI-driven technology to autonomously adjust insulin doses. This innovative system is the first and only FDA-cleared technology to provide automated insulin dose recommendations, thereby reducing the need for constant physician intervention in daily dose adjustments.

For physicians, the d-Nav program offers a robust tool to enhance patient care by ensuring individuals receive precise insulin dosages tailored to their changing physiological needs. Clinical studies have demonstrated significant improvements, with nearly 90 percent of users achieving lower A1C levels within three months, notably without an increased risk of hypoglycemia. The program integrates clinical support, empowering patients to safely and effectively manage their insulin therapy while providing healthcare professionals with a data-driven approach to optimize treatment outcomes and streamline care pathways.

Focus Areas

Digital therapeutics insulin therapy management type 2 diabetes AI-powered insulin dose automation closed-loop system functionality glycemic control A1C reduction hypoglycemia risk reduction chronic disease management

Business Intelligence

Key InvestorsFirstime Ventures, Oakwood Medical, Blue Cross Blue Shield of Michigan
PartnershipsEndocrinology Associates, PA (Arizona); Endocrine Associates of West Village P.C. (New York); Physicians East (North Carolina); Metro Detroit Endocrinology Center (Michigan); Clalit (Israel)
TechnologyAI-powered technology, cloud-based technology, insulin-titration algorithms, d-Nav® Insulin Guidance Service, mobile phone app (iOS/Android)
FDA Clearances1 cleared products (estimated)

What Physicians Need to Know

Core Focus
Hygieia specializes in digital therapeutics for chronic disease management, with a primary focus on insulin therapy management for individuals with Type 2 diabetes.
Advanced Technology
They leverage AI-powered insulin dose automation and closed-loop system functionality to provide precise and personalized therapy adjustments.
Clinical Outcomes
The company aims to achieve significant glycemic control, A1C reduction, and a crucial reduction in hypoglycemia risk for patients.
Regulatory Achievement
Hygieia's AI-driven d-Nav technology is the first and only to earn FDA clearance to automatically adjust insulin doses, a responsibility traditionally held solely by physicians.
Physician Tip

For physicians, Hygieia offers a transformative approach to insulin management. The AI-powered, FDA-cleared automation can significantly reduce the time and effort spent on manual insulin dose adjustments, allowing for more focus on comprehensive patient care. The system's ability to improve glycemic control, lower A1C, and reduce hypoglycemia risk provides a data-driven solution to enhance patient outcomes and safety. Consider Hygieia for patients with Type 2 diabetes who require insulin therapy and could benefit from automated, precise, and continuous dose optimization, potentially leading to better adherence and reduced clinical burden.

While specific integration details for Hygieia's digital therapeutics platform are not provided, digital therapeutic solutions typically integrate with existing healthcare IT systems such as Electronic Health Records (EHRs) for seamless data exchange, patient monitoring, and prescription management. This allows for a holistic view of patient health and streamlined workflows within clinical practices.

Products by Hygieia

1 product in the directory

d-Nav System
Hygieia
Endocrinology & Metabolic AI
Hygieia's d-Nav System is an FDA-cleared, AI-driven mobile app and virtual clinical support program for autonomous insulin dose adjustments in adults with Type 2 diabetes.

What the Web Says

Hygieia appears to be a name used by several distinct companies, including a remote patient monitoring/diabetes management company, a home health care provider, a biological laboratory, and a skincare product line. Reviews vary significantly depending on the specific entity. The remote patient monitoring company and some home health branches generally receive positive feedback regarding work-life balance, supportive colleagues, and making a difference in patients' lives. However, there are also negative comments about management, pay, and high turnover in some home health and laboratory settings. The skincare line has mixed reviews, with some users seeing results and others experiencing no effect and issues with refunds.

Overall: Mixed

Strengths

  • Good work-life balance (for some home health and remote monitoring roles)
  • Supportive colleagues and positive culture (for some healthcare roles)
  • Opportunity to make a difference in patients' lives (healthcare)
  • Flexible working hours (home health)
  • Good benefits package (Hygieia Biological Laboratories, some home health)
  • Products can be effective for some users (skincare)

Limitations

  • Poor management and communication (some home health and laboratory roles)
  • High employee turnover (some home health and laboratory roles)
  • Issues with pay and benefits (Hygieia Biological Laboratories, some home health)
  • Lack of job security and advancement (Hygieia Biological Laboratories, some home health)
  • Ineffective products for some users (skincare)
  • Problems with refunds and customer service (skincare)

Based on reviews from: Indeed.com, US-Reviews, Judge.me, Trustpilot, Reddit

Last updated: 2026-07-18

Videos

News, demos, and interviews about Hygieia.

Loading videos...

Videos load interactively. If none appear, search YouTube for Hygieia →

View all on YouTube

Press & Coverage

Business Wire
Hygieia Extends Series B Round to $22 Million with Participation from Strategic Investors
Hygieia, a digital therapeutics company for insulin therapy, extended its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners. The company's d-Navu00ae technology is the only FDA-cleared technology to autonomously adjust insulin dose recommendations.
2023-05
Medical Device Network
Hygieia secures funding for d-Nav insulin technology - Medical Device Network
Digital therapeutics company Hygieia received a total funding of $22 million in a Series B round to expand the availability of its d-Nav insulin technology. The d-Nav technology is approved by the US FDA for automatically adjusting insulin dose recommendations.
2023-05
Pulse 2.0
Hygieia: Insulin Therapy Company Secures $22 Million
Hygieia, a digital therapeutics company focused on insulin therapy, announced an extension of its Series B funding round to $22 million, with Firstime Ventures leading the investment. Their d-Nav technology is FDA-cleared to autonomously adjust insulin doses, aiming to improve A1C levels for patients.
2023-05
Hygieia Pharmaceuticals
Hygieia Pharmaceuticals Announces First Patient dosed in a US/CN Multi-Center Phase II Clinical Trial Investigating a Long-acting Small Interfering RNA (siRNA) Therapy (Kylo-11) Designed to Lower the Production of Lipoprotein(a) [Lp(a)]
Hygieia Pharmaceuticals announced the first patient has been dosed in a US/CN multi-center Phase II clinical trial for Kylo-11, a siRNA therapy designed to lower lipoprotein(a) (Lp(a)), a risk factor for cardiovascular diseases.
2025-10
DBusiness Daily News
Hygieia in Livonia Closes $17M Funding Round for Digital Insulin Management
Hygieia, a digital health company for insulin management, closed an initial $17 million Series B investment round led by Firstime Ventures. The funding will be used to expand partnerships and access to its d-Nav insulin dose automation technology.
2021-12
Business Wire
Digital Insulin Management Company Hygieia Closes on $17 Million Series B Investment Round
Hygieia, a digital health company focused on insulin management, secured an initial $17 million in Series B funding, led by Firstime Ventures. This investment aims to expand partnerships with endocrinology practices and broaden access to its d-Navu00ae insulin dose automation technology.
2021-12
PR Newswire
Hygieia Receives 510(k) Clearance from FDA for Phone App That Enhances Company's d-Nav Insulin Guidance Service
Hygieia announced it received 510(k) clearance from the FDA for a phone app designed to enhance its d-Navu00ae Insulin Guidance Service. The app is cleared to aid in optimizing insulin management for people with Type 2 diabetes.
2019-02
Yale New Haven Health
Hygieia - Multimodal diagnostic support for rare disease - Yale New Haven Health
Hygieia is a multimodal diagnostic support platform that integrates clinical data, genetic information, and medical knowledge to assist in identifying potential diagnoses and prioritizing risk genes for rare diseases.
unknown

Frequently Asked Questions

Hygieia's d-Nav program is an FDA-cleared, AI-driven digital therapeutic that autonomously adjusts insulin dose recommendations for individuals with type 2 diabetes who inject insulin. It acts as a closed-loop system, providing personalized dose guidance directly to patients via a mobile app, typically adjusting doses every seven days to match changing insulin needs.
Clinical studies have shown that nearly 90% of patients using the d-Nav program achieved lower A1C scores within three months. This significant improvement in glycemic control was accomplished without increasing the risk of hypoglycemia.
The d-Nav program provides continuous, autonomous insulin dose adjustments, reducing the burden on physicians for frequent titration between patient visits. It includes clinical support specialists who monitor data, initiate physician interventions when necessary, and offer personalized patient support, enhancing compliance and freeing up physician time.
Hygieia's primary product is the d-Nav Insulin Management Program, which consists of an AI-powered mobile app and integrated clinical support. The technology is CPT-coded, and new Category III CPT codes were approved to facilitate reimbursement, with the program covered by Medicare, most commercial health plans, and many Medicaid plans.
Hygieia is expanding its clinical partnership program with endocrinology practices across multiple U.S. states, including Michigan, Texas, Arizona, and North Carolina, and holds international licenses in Northern Ireland and Israel. The company demonstrates stability through successful Series B funding, totaling $22 million, and its d-Nav technology being recognized as a standard of medical care by the American Diabetes Association.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.